Generic Valtoco Availability
Last updated on Apr 10, 2025.
Valtoco is a brand name of diazepam, approved by the FDA in the following formulation(s):
VALTOCO (diazepam - spray;nasal)
-
Manufacturer: NEURELIS INC
Approval date: January 10, 2020
Strength(s): 5MG/SPRAY [RLD], 7.5MG/SPRAY [RLD], 10MG/SPRAY [RLD]
Is there a generic version of Valtoco available?
No. There is currently no therapeutically equivalent version of Valtoco available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Valtoco. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Absorption enhancers for drug administration
Patent 10,265,402
Issued: April 23, 2019
Inventor(s): Maggio Edward T.
Assignee(s): Aegis Therapeutics, LLCThe present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various aspects, the invention provides compositions and methods for oral delivery in the form of a tablet.
Patent expiration dates:
- May 11, 2025✓
- May 11, 2025
-
Administration of benzodiazepine compositions
Patent 11,241,414
Issued: February 8, 2022
Inventor(s): Cartt Steve & Medeiros David & Gwozdz Garry Thomas & Loxley Andrew & Mitchnick Mark & Hale David F. & Maggio Edward T.
Assignee(s): Neurelis, Inc.The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.
Patent expiration dates:
- March 27, 2029✓
- March 27, 2029
-
Administration of benzodiazepine compositions
Patent 11,793,786
Issued: October 24, 2023
Inventor(s): Cartt; Steve et al.
Assignee(s): Neurelis, Inc. (San Diego, CA)The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.
Patent expiration dates:
- March 27, 2029✓
- March 27, 2029
-
Administration of benzodiazepine compositions
Patent 8,895,546
Issued: November 25, 2014
Inventor(s): Cartt Steve & Medeiros David & Gwozdz Garry Thomas & Loxley Andrew & Mitchnick Mark & Hale David & Maggio Edward T.
Assignee(s): Hale Biopharma Ventures, LLCThe invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.
Patent expiration dates:
- March 27, 2029✓
- March 27, 2029
-
Absorption enhancers for intranasal administration
Patent 8,927,497
Issued: January 6, 2015
Inventor(s): Maggio Edward T.
Assignee(s): Aegis Therapeutics, LLC.A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.
Patent expiration dates:
- July 21, 2025✓✓
- July 21, 2025
-
Pharmaceutical composition including alkyl glycoside and an anti-seizure agent
Patent 9,642,913
Issued: May 9, 2017
Inventor(s): Maggio Edward T.
Assignee(s): Aegis Therapeutics, LLC.A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.
Patent expiration dates:
- May 11, 2025✓
- May 11, 2025
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- January 10, 2027 - INDICATED FOR THE ACUTE TX OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E. SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT’S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 6 YEARS OF AGE AND OLDER
More about Valtoco (diazepam)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Latest FDA alerts (2)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: benzodiazepine anticonvulsants
- Breastfeeding
- En español
Patient resources
Other brands
Valium, Diastat, Diastat AcuDial, Diazepam Intensol, ... +3 more
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
